| 前收市價 | 16.67 |
| 開市 | 16.55 |
| 買盤 | 15.94 x 100 |
| 賣出價 | 16.15 x 100 |
| 今日波幅 | 15.74 - 16.64 |
| 52 週波幅 | 11.83 - 28.80 |
| 成交量 | |
| 平均成交量 | 671,331 |
| 市值 | 787.135M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -6.02 |
| 業績公佈日 | 2024年7月31日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 39.83 |
ZacksRegenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -7.81% and 37.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Motley FoolDoes This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant.
ZacksREGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
